rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Journey Medical Corporation

DERM · Nasdaq

Health CarePharmaceuticalsNot moving yet

DERM stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 33 weeks. It is 18.5% below that average now. Pharmaceuticals: 35% of its 74 stocks in an uptrend (−4 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 33
Industry in uptrend
35% -4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
72 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

23 Apr – 22 Oct
27%37%47%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$782K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders72+3 on the quarter
New · exited26 · 23
Reported value$75.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
WASATCH ADVISORS LPadded · filed 10 Jul 20262,858,930$20.2M+725,560+34.0%
TANG CAPITAL MANAGEMENT LLCunchanged · filed 14 Aug 20261,610,000$11.4M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026675,185$4.8M-406,895−37.6%
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.new · filed 14 Aug 2026536,000$3.8M+536,000
Pale Fire Capital SEadded · filed 13 Aug 2026528,584$3.7M+46,597+9.7%
Opaleye Management Inc.reduced · filed 14 Aug 2026350,000$2.5M-610,000−63.5%
Summit Financial, LLCreduced · filed 12 Aug 2026346,748$2.5M-33,059−8.7%
JANE STREET GROUP, LLCnew · filed 14 Aug 2026320,021$2.3M+320,021
Diametric Capital, LPadded · filed 14 Aug 2026295,663$2.1M+99,251+50.5%
Ikarian Capital, LLCunchanged · filed 14 Aug 2026251,436$1.8M00.0%
31 Mar 2023 – 30 Jun 2026
154473Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Justin Adam Smith Company insiderDirector · last 1 Jul 20262 · 0
Miranda Jayne Toledano Company insiderDirector · last 1 Jul 20260 · 0
Neil Herskowitz Company insiderDirector · last 1 Jul 20260 · 0
Lindsay A. Rosenwald Company insiderDirector · last 25 Jun 20263 · 0
Michael Cooper Pearce Company insiderDirector · last 25 Jun 20260 · 0
Claude Maraoui Company insiderPresident & CEO · last 22 Apr 20262 · 10
Joseph Benesch Company insiderCFO · last 22 Apr 20260 · 7
Ramsey Alloush Company insiderChief Operating Officer · last 22 Apr 20260 · 1
Jeffrey Paley Company insiderDirector · last 28 Nov 20232 · 3
Fortress Biotech, Inc. Company insider10% owner · last 12 May 20230 · 0
Paolantonio Ernest Robert De Company insiderOfficer · last 4 Oct 20220 · 2

Same industry

ABBV AbbVieLeading+19%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202566.2%
Operating profit marginFY 2025 · to 31 Dec 2025-13.2%
Free cash flow marginFY 2024 · to 31 Dec 2024-43.0%
Return on capital employedFY 2025 · to 31 Dec 2025-14.3%
Debt to equityFY 2025 · to 31 Dec 20250.79×
Interest coverFY 2025 · to 31 Dec 2025-2.21×
Research spendFY 2025 · to 31 Dec 20250.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$24.1M
Free cash flowFY 2024 · to 31 Dec 2024−$24.1M

Analyst forecasts

No analyst forecasts yet.